Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Recruiting 3

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 2Sarcoma 1Gynecologic 1

Conditions

Sarcoma, Endometrial Stromal 1Perivascular Epithelioid Cell Neoplasms 1Breast Neoplasms 1Advanced Breast Cancer 1Adenosarcoma of the uterus 1

Interventions

Magnetic Resonance Spectroscopy 283Specimen Handling 278pembrolizumab 255Cyclophosphamide 234Radiotherapy 229Nivolumab 183Cisplatin 174Biopsy 165Carboplatin 155Radiosurgery 142fludarabine 130Blood Specimen Collection 130Gemcitabine 120Surveys and Questionnaires 117Paclitaxel 115venetoclax 112Standard of Care 112Dexamethasone 105Bevacizumab 96Radiation 95Rituximab 91Oxaliplatin 89Cytarabine 88Capecitabine 86Drug Therapy 85Ipilimumab 83Doxorubicin 81durvalumab 80fludarabine phosphate 73Fluorouracil 72

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × RAD1901 × 90 days × Clear all
NCT07467772 2026-05-22

Ph 2 Elacestrant in ER Positive Uterine Sarcomas

Dana-Farber Cancer Institute

Phase 2 Recruiting
30 enrolled
GynecologicSarcoma

Adenosarcoma of the uterus, Sarcoma, Endometrial Stromal, Perivascular Epithelioid Cell Neoplasms

NCT07198724 2026-04-09

ERADICATE

Dana-Farber Cancer Institute

Phase 1/2 Recruiting
65 enrolled
Breast

Breast Neoplasms

NCT06382948 2026-04-03

ADELA

MedSIR

Phase 3 Recruiting
240 enrolled
Breast

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡